Insider · CIK 0001532475
Mark Alan Goldberg
Files at BPMC (Blueprint Medicines Corp). First filing -, latest -.
In brief
Mark Alan Goldberg files SEC Form 4 as director at BPMC (Blueprint Medicines Corp). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Mark Alan Goldberg has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Oct 30, 2023 | ImmunoGen, Inc. | 10,000 0.00% of outstanding | $151k | Oct 30, 2023 | none |
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Common Stock | -3,902 | - | - | 18,254 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | UTender of shares Common Stock | -18,254 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,909 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -7,500 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -4,875 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -4,500 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -4,500 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -5,300 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -5,300 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -4,570 | - | - | 0 | Jul 21, 2025 |
| Jun 18, 2025 | BPMC Blueprint Medicines Corp | AGrant or award Common Stock | +3,902 | $128.12 | $500k | 22,156 | Jun 24, 2025 |
Questions about Mark Alan Goldberg
Answered from the filings on this page, as of the latest one.
Is Mark Alan Goldberg buying or selling?
Mark Alan Goldberg has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Mark Alan Goldberg's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Mark Alan Goldberg has 0.
Where does Mark Alan Goldberg file Form 4?
Mark Alan Goldberg has filed Form 4 at BPMC (Blueprint Medicines Corp). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.